Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 349:397, 1997.
Aronow WS et al. Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am J Cardiol 79:1432-3, 1997.
Berger PB et al. Increase in total plasma homocysteine concentration after cardiac
transplantation. Mayo Clin Proc 70:125-31, 1995.
Boers GHJ et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313:709-15, 1985.
Boers GH. Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease. Neth J Med 45(1):34-41, 1994.
Boushey CJ, Beresford AA, Omenn GS, Motulsky AR. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274(13):1049-57, 1995.
Brattström LE et al. Moderate homocysteinemia: A possible risk factor for arteriosclerotic
cerebrovascular disease. Stroke 15(6):1012-16, 1984.
Brattström LE et al. Folic acid responsive postmenopausal homocysteinemia. Metabolism 34(11):1073-7, 1985.
Brattström LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid - An innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48(3):215-21, 1988.
Brattström L et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral
occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81(1):51-60, 1990.
Brattström L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationship to type of stroke and stroke risk factors. Eur J Clin Invest 22(3):214-21, 1992.
Brattström L. Vitamins as homocysteine-lowering agents: A mini review. Pres. at the Am. Inst. of Nutr. Coll., April 13, 1995, Atlanta, Georgia; Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 126(4 Suppl):1276S-1280S, 1996.
Boushey CJ, Beresford AA, Omenn GS, Motulsky AR. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274(13):1049-57, 1995.
Candito M et al. Fasting homocysteine in acute coronary disease and homocysteine response to methionine challenge three months after myocardial infarction. Nutri Metabol Cardiovasc Dis 6:90, 1996.
Capri J. Homocysteine rivals smoking for risk of CAD. Family Practice News August 1, 1996:40-1.
Clarke R et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324(17):1149-55, 1991.
Dalery K et al. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate and folate. Am J Cardiol 75:1107-11, 1995.
De Keyser J, De Klippel N, Merkx H et al. Serum concentrations of vitamins A and E and early outcome after ischaemic stroke. Lancet 339:1562-5, 1992.
Den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 345:882-5, 1995.
Dudman NP, Wilcken DE, Wang J, et al. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Throm 13(9):1253-60, 1993.
Dudman NP, Guo XW, Gordon RB, et al. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J Nutr 126(4 Suppl):1295S-300S, 1996.
Glueck CJ et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 75:132-6, 1995.
Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 277(22):1775-81, 1997.
Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of
endothelial injury and platelet response to its genesis. J Clin Invest 58(3):731-41, 1976.
Hopkins P, Wu L, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 15(9):1314-20, 1995.
Israelsson B et al. Homocysteine and myocardial infarction. Atherosclerosis 71(2-3):227-33, 1988.
Jacques P, Bostom A, Williams R, et al. Relation between folate status, a common mutation in methylene tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93(1):7-9, 1996.
Klevay LM. The homocysteine theory of arteriosclerosis. Letter. Nutr Rev 50(5):155, 1992.
Koehler KM, Romero LJ, Stauber PM, et al. Vitamin supplementation and other variables affecting serum homocysteine and methylmalonic acid concentrations in elderly men and women. J Am Coll Nutr 15(4):364-76, 1996.
Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction. J Intern Med 237(4):381-8, 1995.
Lussier-Cacan S, Xhignesse M, Piolot A, et al. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 64:587-93, 1996.
Manilow; M.R.: Hyperhomocysteinemia: A Common and Easily Reversible Risk Factor for Occlusive Atherosclerosis; Circulation, 81; 1990; 2004-6.
McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22(2):215-27.
McCully KS, Vezeridis MP. Homocysteine thiolactone in arteriosclerosis and cancer. Res Commun Chem Pathol Pharmacol 1988; 59(1):107-19.
McCully KS. Homocysteine arteriosclerosis: failure to isolate homocysteine thiolactone from plasma and lipoproteins. Res Commun Chem Pathol Pharmacol 1989; 63(2):301-4.
McCully; Kilmer. S.D.: Atherosclerosis, Serum Cholesterol and the Homocysteine Theory - A Study of 194 Consecutive Autopsies; The American Journal of Medical Sciences 1990;299(4): 217-221.
Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 275(24):1893-6, 1996.
Mudd SH et al. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum
Genet 33:883-93, 1981.
Mudd SH, Levy HL. Plasma homocyst(e)ine or homocysteine? Letter. N Engl J Med 333(5):325, 1995.
Murphy-Chutorian DR et al. Methionine intolerance: A possible risk factor for coronary artery disease. J Am Coll Cardiol 6:725, 1986.
Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274(19):1526-33, 1995.
Nygård O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-6, 1997.
Olszewski AJ et al. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Scand J Clin Lab Invest 48(3):215-21, 1988.
Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in ischemic heart disease. Atherosclerosis 69(2-3):109-13, 1988.
Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low Dose Betaine Supplementation Leads to Immediate and Long Term Lowering of Plasma Homocysteine in Healthy Men and Women. Journal of Nutrition 2003;133(12):4135-4138.
Oriot D, Beharry K, Gordon JB, Aranda JV. Ascorbic acid during cerebral ischemia in newborn
piglets. Acta Paediatr 84:621-6, 1995.
Oster KA. The treatment of bovine xanthine oxidase initiated atherosclerosis by folic acid. Clin Res 24:512A, 1976.
Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 59:940-9, 1994.
Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346:1395-8, 1995.
Povoa H Jr et al. Folic acid and lipoprotein lipase from aorta and blood plasma of atherosclerotic rats. Biomed Biochim Acta 43(2):241-4,1984.
Ravnskov, Uffe: Kolesterolmyten - Fettet i din föde giver ikke hjärteinfarkt! - Streiffert & Co Bokförlag; 1991, ISBN 91-7886-085-7.
Reis RP II et al. Homocysteinemia after methionine overload as a coronary artery disease risk factor: importance of age and homocysteine levels. Coronary Art Dis 6(11):851-6, 1995.
Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 92(10):2825-30, 1995.
Rosenberg IH, Bostom A, Jacques P, Selhub J. Gene-nutrient interactions in plasma homocysteine regulation. Curr Opin Endocrinol Diabetes 3:497-500, 1996.
Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332(5):286-91, 1995.
Schnyder G. et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001 Nov 29;345(22):1593-600.
Stabler; S.P., Allen; R.H., Lindenbaum, J.: Vitamin B-12 defieciency in the elderly: current dilemmas; American Journal of Clinical Nutrition; 66:4, October 1987; 741-9.
Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268(7):877-81, 1992.
Stampfer MJ, Malinow MR. Can lowering homocysteine reduce cardiovascular risk? Editorial. N Engl J Med
332(5):328-9, 1995.
Szostak WB. Homocysteine and cardiovascular disease. Eur J Clin Nutr 45(suppl 2):110-12, 1991.
Tonstad S et al. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Ped Res 40(1):47-52, 1996.
Ubbink JB, Vermaak WJ, Bennett JM, et al. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 69(12):527-34, 1991.
Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993.
Ubbink J et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124:1927-33, 1994.
Ubbink JB, Hayward Vermaak WJ, Delport R, et al. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr 62:802-8, 1995.
Ubbink JB et al. Will an increased dietary folate intake reduce the incidence of cardiovascular disease? Nutr Rev 54(7):213-16, 1996.
Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disaese: Plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease, in RBJ Francis, Ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, Marcel Dekker, Inc. 1992:183-236.
Van Den Berg M et al. Combined vitamin B6 plus folic acid therapy in young patients with
arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 20:933-40, 1994.
Verhoef P, Hennekens CH, Malinow MR, et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 25(10):1924-30, 1994.
Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamin B6, B12 and folate. Am J Epidemiol143(9):845-59, 1996.
Verhoef P et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis.
Arteriosclerosis Thromb Vasc Biol 17:989-95, 1997.
Welch GN et al. Homocysteine, oxidative stress, and vascular disease. Hospital Practice, June 15, 1997;81-92.
Se også "Aminosyrer, kilder til" her
